

Annex № 4
To Art. 12, par. 1, it.1, art.14 of Ordinance № 2 from
09.11.2021
And Regulation (EU) 596/2014 of the European
Parliament and of the Council
of 16 April 2014

INFORMATION ABOUT THE FACTS AND CIRCUMSTANCES OCCURRED
DURING THE FIRST QUARTER OF 2022
OF "SOPHARMA" AD

- 1.1. No change in the persons controlling the Company.
- 1.2. No opening of bankruptcy proceedings against the company or its subsidiary or any significant events related to production.
- 1.3. No conclusion or execution of significant transactions.
- 1.4. No decision on conclusion, termination and cancellation of joint venture agreements.
- 1.5. Change of the auditors of the company - At the Regular General Meeting of Shareholders of "SOPHARMA" AD, held on 4 June 2021, the auditing company "BAKER TILLY KLITOU AND PARTNERS" OOD, based in Sofia, Acad. "Ivan Evst. Geshov " 104, for a registered auditor for inspection and certification of the Annual Financial Statements of the Company.
- 1.6. There is no opening or termination of a court or arbitration case relating to the debts or claims of the company or its subsidiary with a claim price of at least 10% of the company's equity.
- 1.7. No purchases, sales or established pledges of shares in commercial companies by the issuer or its subsidiary.
- 1.8. On February 24, 2022, Russian military forces started hostile invasion in Ukraine. Subsequently, a number of countries imposed sanctions on certain individuals and legal entities in Russia. It is expected that the war in Ukraine and related economic sanctions and other measures taken by governments around the world will have a significant impact on both local and global economies.
The management of Sopharma AD believes that the unprovoked invasion of the Russian army into Ukraine could seriously affect the activities of the Company, as about 40% of sales of products are realized in Ukraine and Russia. At this stage, the company has reduced its activity in these markets, including due to logistical inability to make deliveries. As of the date of approval of these separate financial statements, the Company has no commercial counterparties included in sanctions lists published by the European Union.
The company owns investments in two subsidiaries in Ukraine. As of December 31, 2021 the amount of the investment in the subsidiary Sopharma Ukraine is BGN 9,669 thousand and the amount of the investment in the subsidiary Vitamini is BGN 1,283 thousand. As of the date of approval of these separate financial statements the assets of these subsidiaries companies are not physically affected by military activities, but it may be necessary in the future to reconsider the value of these investments depending on the development of the war and its impact on the activities of companies.

"Sopharma" AD informs all interested parties that the interim financial statements of the Company as at 31 March 2022 have not been verified by a registered auditor.

This is a translation from Bulgarian of the Individual financial statements
of "Sopharma" AD.
In case of divergence Bulgarian text should prevail.